Floatz Rating
D30/100
Confidence
Indicative
Sponsor
University of Zurich
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Systemic Amyloidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Florbetaben (this asset) | University of Zurich | N/A | D · 30 |
| Adriamycin | Margarida Magalhaes-Silverman | P2 | B |
| Dexasone | Margarida Magalhaes-Silverman | P2 | B |
| Melphalan | Margarida Magalhaes-Silverman | P2 | B |
| Bortezomib | Margarida Magalhaes-Silverman | P2 | B |
| Cyclophosphamide | Margarida Magalhaes-Silverman | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Margarida Magalhaes-Silverman | P2 | B |
| Etoposide | Margarida Magalhaes-Silverman | P2 | B |
| Evuzamitide | University of Tennessee Graduate School of Medicine | P1/2 | B |
+16 more in the Primary Systemic Amyloidosis cohort
Other indications for Florbetaben
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P4 | BBB · 73 |
| AL Amyloidosis | — | P3 | B · 60 |
| Amyotrophic Lateral Sclerosis | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Florbetaben in Primary Systemic Amyloidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/florbetaben-primary-systemic-amyloidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →